Addressing the issue of whether a comprehensive reference listing of every relevant antisense oligodeoxynucleotide in a known nucleic acid sequence anticipates claims to specific antisense sequences, the U.S.
Prior Art Reference Need Not Disclose Claimed Invention's Utility
Addressing the issue of whether a comprehensive reference listing of every relevant antisense oligodeoxynucleotide in a known nucleic acid sequence anticipates claims to specific antisense sequences, the U.S. Court of Appeals for the Federal Circuit held that anticipation merely requires that the oligonucleotide sequence was in the prior art, not that its usefulness was previously disclosed.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.






